Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Scorpion Therapeutics, Inc.

Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Kα Inhibitor STX-478
From Scorpion Therapeutics, Inc.
Via Business Wire
Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended to Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Presents Initial Clinical Data From Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid Tumors at ESMO Congress 2024
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at ESMO Congress 2024
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics to Present Preclinical Data for Potential Best-in-Class Mutant-Selective PI3Kα Inhibitor at San Antonio Breast Cancer Symposium
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory Board
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data for STX-721, a Next-Generation Exon 20 Mutant EGFR Inhibitor, at the EORTC-NCI-AACR Symposium 2022
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics to Present Preclinical Proof-of-Concept Data for Highly Selective, Next-Generation Exon 20 Mutant EGFR Inhibitor at 34th EORTC-NCI-AACR Symposium
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate with a Best-in-Class Profile
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics to Present at Jefferies Healthcare Conference
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Announces Discovery Scientific Advisory Board
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data Supporting the Development of Its Potentially Best-in-Class Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors at the AACR Annual Meeting 2022
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. to its Board of Directors
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Reveals Highly-selective Lead Programs Targeting Mutant PI3Kα and EGFR Exon 20, Two Established Cancer Drivers with Broad Therapeutic Applicability
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Announces Appointment of Brian Piper as Chief Financial Officer
From Scorpion Therapeutics, Inc.
Via Business Wire
Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D.
From Scorpion Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.